CN102459268A - 二氮杂高金刚烷衍生物和其使用方法 - Google Patents

二氮杂高金刚烷衍生物和其使用方法 Download PDF

Info

Publication number
CN102459268A
CN102459268A CN2010800368013A CN201080036801A CN102459268A CN 102459268 A CN102459268 A CN 102459268A CN 2010800368013 A CN2010800368013 A CN 2010800368013A CN 201080036801 A CN201080036801 A CN 201080036801A CN 102459268 A CN102459268 A CN 102459268A
Authority
CN
China
Prior art keywords
undecane
diaza tricyclic
pyridin
tricyclic
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800368013A
Other languages
English (en)
Chinese (zh)
Inventor
M.R.施林普夫
K.B.西皮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
|abbvie|gong Si
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43354879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102459268(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CN102459268A publication Critical patent/CN102459268A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
CN2010800368013A 2009-06-19 2010-06-18 二氮杂高金刚烷衍生物和其使用方法 Pending CN102459268A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21847909P 2009-06-19 2009-06-19
US61/218479 2009-06-19
PCT/CN2010/000889 WO2010145208A1 (en) 2009-06-19 2010-06-18 Diazahomoadamantane derivatives and methods of use thereof

Publications (1)

Publication Number Publication Date
CN102459268A true CN102459268A (zh) 2012-05-16

Family

ID=43354879

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800368013A Pending CN102459268A (zh) 2009-06-19 2010-06-18 二氮杂高金刚烷衍生物和其使用方法

Country Status (15)

Country Link
US (1) US8846661B2 (enExample)
EP (1) EP2443122B1 (enExample)
JP (1) JP2012530084A (enExample)
KR (1) KR20120044978A (enExample)
CN (1) CN102459268A (enExample)
AU (1) AU2010262643B2 (enExample)
BR (1) BRPI1015043A2 (enExample)
CA (1) CA2765466A1 (enExample)
IL (2) IL216883A (enExample)
MX (1) MX2011014019A (enExample)
NZ (1) NZ597511A (enExample)
PE (1) PE20121066A1 (enExample)
RU (2) RU2549551C2 (enExample)
SG (1) SG176921A1 (enExample)
WO (1) WO2010145208A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111971280A (zh) * 2018-02-08 2020-11-20 耶路撒冷希伯来大学伊萨姆研究发展公司 杂芳基化合物、其药物组合物和其治疗用途

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2809028C (en) * 2010-08-20 2019-04-09 Research Triangle Institute Nicotinic receptor compounds
CN103087001A (zh) * 2011-11-03 2013-05-08 南京大学 香草酸的1，3，4-噁二唑衍生物及其制法和用途
WO2014165090A1 (en) * 2013-03-13 2014-10-09 The Broad Institute, Inc. Compounds for the treatment of tuberculosis
RU2552649C1 (ru) * 2013-12-13 2015-06-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет тонких химических технологий имени М.В. Ломоносова" (МИТХТ им. М.В. Ломоносова) Душистые 5-бензил-1,3-диазаадамантан-6-оны
WO2015103005A1 (en) * 2014-01-03 2015-07-09 Research Institute At Nationwide Children's Hospital Amphiphilic amine compounds and their use as therapeutic agents and nanocarriers
WO2016100184A1 (en) 2014-12-16 2016-06-23 Forum Pharmaceuticals, Inc. Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
JP2018516973A (ja) 2015-06-10 2018-06-28 フォーラム・ファーマシューティカルズ・インコーポレイテッドＦｏｒｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． α７−ニコチン性アセチルコリン受容体のアゴニストとしてのアミノベンゾイソオキサゾール化合物
EP3334740A4 (en) 2015-08-12 2019-02-06 Axovant Sciences GmbH GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF ALPHA 7-NICOTINIC ACETYLCHOLINE RECEPTORS
CN108697709A (zh) * 2015-12-10 2018-10-23 Ptc医疗公司 用于治疗亨廷顿病的方法
AU2018282154B2 (en) 2017-06-05 2022-04-07 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
WO2019005993A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
WO2020005877A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4557865A (en) * 1984-05-07 1985-12-10 Pennwalt Corporation Substituted 4-azatricyclo[4.3.1.13,8 ]undecane compounds
CA2348879A1 (en) * 1998-11-02 2000-05-11 Welfide Corporation Pyrrolidine compound and pharmaceutical use thereof
WO2008058096A2 (en) * 2006-11-06 2008-05-15 Abbott Laboratories Azaadamantane derivatives and their uses as nicotinic acetylcholine receptors ligands
WO2008118743A1 (en) * 2007-03-23 2008-10-02 Abbott Laboratories Acetamide and carboxamide derivatives of azaadamantane and methods of use thereof
WO2008118747A1 (en) * 2007-03-23 2008-10-02 Abbott Laboratories Amimomethyl azaadamantane derivatives and use thereof as selective modulators of the alpha7- neuronal nicotinic acetylcholine receptor (nnrs)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2162469C2 (ru) * 1995-11-02 2001-01-27 Ньюросерч А/С Конденсированные тропановые производные в качестве ингибиторов обратного захвата нейромедиаторов
EE200100096A (et) * 1998-08-18 2002-06-17 Ucb, S.A. Asatsüklilise tüvistruktuuriga tsükliline ühend, seda sisaldav farmatseutiline kompositsioon ning selle kasutamine ravimina
CA2450167A1 (en) * 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
US20050065178A1 (en) * 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
US7482338B2 (en) * 2003-09-26 2009-01-27 Astrazeneca Ab Non-amide nonanes
TW200840569A (en) * 2007-03-13 2008-10-16 Targacept Inc Sub-type selective amides of diazabicycloalkanes
MX2009010174A (es) * 2007-03-23 2009-10-12 Abbott Lab Derivados de aza-adamantano ester y carbamato y metodos de uso de los mismos.
CA2771885C (en) 2009-09-14 2014-04-08 Suven Life Sciences Limited 1,2-dihydro-2-oxoquinoline compounds as 5-ht4receptor ligands

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4557865A (en) * 1984-05-07 1985-12-10 Pennwalt Corporation Substituted 4-azatricyclo[4.3.1.13,8 ]undecane compounds
CA2348879A1 (en) * 1998-11-02 2000-05-11 Welfide Corporation Pyrrolidine compound and pharmaceutical use thereof
CN1332726A (zh) * 1998-11-02 2002-01-23 卫福有限公司 吡咯烷化合物及其药物用途
WO2008058096A2 (en) * 2006-11-06 2008-05-15 Abbott Laboratories Azaadamantane derivatives and their uses as nicotinic acetylcholine receptors ligands
WO2008118743A1 (en) * 2007-03-23 2008-10-02 Abbott Laboratories Acetamide and carboxamide derivatives of azaadamantane and methods of use thereof
WO2008118747A1 (en) * 2007-03-23 2008-10-02 Abbott Laboratories Amimomethyl azaadamantane derivatives and use thereof as selective modulators of the alpha7- neuronal nicotinic acetylcholine receptor (nnrs)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111971280A (zh) * 2018-02-08 2020-11-20 耶路撒冷希伯来大学伊萨姆研究发展公司 杂芳基化合物、其药物组合物和其治疗用途

Also Published As

Publication number Publication date
KR20120044978A (ko) 2012-05-08
NZ597511A (en) 2014-01-31
IL216883A0 (en) 2012-02-29
AU2010262643A1 (en) 2012-02-02
CA2765466A1 (en) 2010-12-23
WO2010145208A1 (en) 2010-12-23
EP2443122B1 (en) 2014-03-05
RU2012101784A (ru) 2013-07-27
US20100324027A1 (en) 2010-12-23
MX2011014019A (es) 2012-02-22
RU2549551C2 (ru) 2015-04-27
US8846661B2 (en) 2014-09-30
EP2443122A1 (en) 2012-04-25
BRPI1015043A2 (pt) 2019-07-09
SG176921A1 (en) 2012-01-30
IL236830A0 (en) 2015-03-31
AU2010262643B2 (en) 2015-02-19
EP2443122A4 (en) 2012-12-19
RU2015110025A (ru) 2015-08-20
IL216883A (en) 2015-02-26
JP2012530084A (ja) 2012-11-29
PE20121066A1 (es) 2012-09-13

Similar Documents

Publication Publication Date Title
CN102459268A (zh) 二氮杂高金刚烷衍生物和其使用方法
CA2902781C (en) Novel pyrazole derivative
AU2021200164B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
TW200829243A (en) Azaadamantane derivatives and methods of use
TW200526667A (en) Substituted diazabicycloalkane derivatives
KR102794907B1 (ko) Pde1 억제제로서의 치환된 푸라노피리미딘 화합물
CN109661396A (zh) 作为rock抑制剂的螺稠合环状脲
EP2855453A1 (en) Benzimidazole-proline derivatives
TW200930375A (en) Benzofuropyrimidinones
CN101925599A (zh) 作为烟碱性乙酰胆碱受体活性调节剂的联芳基取代的氮杂双环烷衍生物
CN103145711A (zh) 氮杂金刚烷酯和氨基甲酸酯衍生物及其使用方法
CN102690265A (zh) 4-取代的氮杂金刚烷衍生物及其使用方法
KR102640696B1 (ko) Pde7 억제제로서 치환된 벤즈옥사졸 및 벤조푸란 화합물
CN101641356B (zh) 氮杂金刚烷的乙酰胺和甲酰胺衍生物及其使用方法
CN102958932A (zh) 5-ht受体调节剂及其使用方法
CN102686586A (zh) 组胺h3反相激动剂和拮抗剂及其使用方法
WO2020007964A1 (en) 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
AU2015202090A1 (en) Diazahomoadamantane derivatives and methods of use thereof
CN101238125A (zh) 5-吡啶基-1-氮杂双环[3.2.1]辛烷衍生物，其制备方法及其在药物中的应用
OA19667A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment.
HK40036192B (en) Substituted furanopyrimidine compounds as pde1 inhibitors
HK40036192A (en) Substituted furanopyrimidine compounds as pde1 inhibitors
OA20303A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment.
CN101568541A (zh) 螺环氮杂金刚烷衍生物和使用方法
HK1135972B (en) 4-substituted azaadamantane derivatives and methods of use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ABBVIE COMPANY

Free format text: FORMER OWNER: ABBOTT GMBH. + CO. KG

Effective date: 20130620

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130620

Address after: Illinois State

Applicant after: |ABBVIE|Gong Si

Address before: Illinois State

Applicant before: Abbott GmbH. & Co. Kg

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120516